Home > Journals > Panminerva Medica > Past Issues > Articles online first > Panminerva Medica 2021 Sep 06

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

Panminerva Medica 2021 Sep 06

DOI: 10.23736/S0031-0808.21.04511-0

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Metabolic syndrome and prostate cancer treatment

Alessandro MORLACCO 1 , Fabio ZATTONI 2, Matteo SOLIGO 2, Valeria LAMI 1, Massimo IAFRATE 1, Nicola ZANOVELLO 1, Fabrizio DAL MORO 1

1 Department of Surgery, Oncology and Gastroenterology, Urology Clinic, University of Padova, Padova, Italy; 2 Urology Clinic, University Hospital Santa Maria della Misericordia, Udine, Italy


PDF


Metabolic syndrome (MetS) has been linked with several human cancers. Prostate cancer is the most common neoplasm in male adults and is often treated with radical prostatectomy (RP). Given the complex hormonal and metabolic alteration present in MetS, a possible role in the development and progression of prostate cancer (PCa) has been hypothesized. Several studies have investigated the connections between MetS and the risk of developing prostate cancer, as well as the oncological outcomes of patients who already suffer from PCa and receive a radical treatment. This comprehensive review explores the available evidence dealing with MetS and the oncological and functional results of RP for PCa.


KEY WORDS: Prostate cancer; Prostate MRI; mpMRI; Negative MRI; Clinically-significant pCa

top of page